Christopher Richard Hibberd

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.

Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel.